Difference between revisions of "CNS carcinoma"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
|- | |- | ||
|} | |} | ||
| + | <big>This page has regimens that are not specific to any one type of cancer. For disease-specific regimens, please go to the following pages: | ||
| + | *[[Breast cancer, CNS metastases]] | ||
| + | *[[Non-small cell lung cancer, CNS metastases]] | ||
| + | </big> | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 12:00, 27 January 2023
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
This page has regimens that are not specific to any one type of cancer. For disease-specific regimens, please go to the following pages:
1 regimens on this page
1 variants on this page
|
Guidelines
ASCO
- 2022: Schiff et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
- 2022: Ramakrishna et al. Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Older
- 2018: Ramakrishna et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline update PubMed
- 2014: Ramakrishna et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline PubMed
ASCO/SNO/ASTRO
- 2021: Vogelbaum et al. Treatment for Brain Metastases
EANO/ESMO
- 2021: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
- 2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
NCCN
All lines of therapy
Whole brain irradiation
WBRT: Whole-Brain Radiation Therapy
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Knisely et al. 2007 (RTOG 0118) | 2002-2004 | Phase 3 (C) | Thalidomide & WBRT | Did not meet primary endpoint of OS |
References
- RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article contains dosing details in abstract PubMed NCT00033254